In the BioHarmony Drug Report Database

"Preview" Icon

Brolucizumab

Beovu (brolucizumab) is an antibody pharmaceutical. Brolucizumab was first approved as Beovu on 2019-10-07. It is used to treat wet macular degeneration in the USA. It has been approved in Europe to treat wet macular degeneration. The pharmaceutical is active against vascular endothelial growth factor A.

 

Trade Name

 

Beovu
 

Common Name

 

brolucizumab
 

ChEMBL ID

 

CHEMBL3707357
 

Indication

 

wet macular degeneration
 

Drug Class

 

Monoclonal antibodies: humanized, cardiovascular indications

Image (chem structure or protein)

Brolucizumab structure rendering